A combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV

摘要

A combination of at least two direct acting antiviral agents (DAAs) for use in the treatment of HCV, wherein the at least two DAAs comprise PSI-7977 and GS-5885, and the treatment does not include administration of interferon or ribavirin, and wherein Treatment continues for 8, 9, 10, 11, or 12 weeks, and the treatment is for a patient infected with HCV genotype 1.